Biopharma Insights

A Booming Anti-Obesity Drug Discovery Landscape at a Glance (With Challenges)

In 1986, Danish scientist Jens Juul Holst discovered that the gut hormone GLP-1 stimulates insulin and suppresses appetite. This research led to the development of two blockbuster weight-loss drugs: Wegovy …

Continue ›››

This Company Anonymized 1.8 Trillion Records to Support Biomedical Research

In the rapidly evolving life sciences and healthcare landscape, the secure and privacy-preserving exchange and linkage of health data is paramount. The topic of biomedical data collection and processing received …

Continue ›››

85% of Healthcare Leaders Investing or Plan to Invest in Gen AI, According to the Largest Survey

Among many important helathcare tech topics discussed at the inagural HLTH Europe 2024 conference taking place on June 17-20 in Amsterdam, generative artificial intelligence (AI) has seemingly taken the central …

Continue ›››

The Rise of Cyclic Peptides: Bridging the Gap in Modern Medicine

Cyclic peptides, characterized by their unique ring structures, represent an emerging trend in drug discovery due to their ability to bridge the gap between small molecules and biologics.

Continue ›››

Insilico Medicine Unveils nach0: A Comprehensive LLM for Chemical and Biomedical Applications

Insilico Medicine, a clinical-stage AI-driven drug discovery company, in collaboration with NVIDIA, has introduced nach0, a novel large language model (LLM) transformer designed for biological and chemical tasks. Detailed in …

Continue ›››

4 Biotech Startups Developing Breakthrough Drug Modalities

In the dynamic world of drug discovery, companies must continually innovate beyond their existing drug portfolios and modalities. Relying solely on familiar modalities limits the potential to develop more effective …

Continue ›››

The Growing Impact of AI in Healthcare

The advent of artificial intelligence (AI) in healthcare has catalyzed an epoch of change, reshaping diagnostic procedures, therapeutic strategies, and patient monitoring processes, as well as the very ability to …

Continue ›››

From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development

Drug development for rare (also referred to as orphan) diseases is notoriously challenging. Legislative initiatives, such as the 1983 US Orphan Drug Act and 1999 EU Orphan Regulation, provide regulatory …

Continue ›››

Optimising Drug Discovery R&D with Graphs

Data in Life Sciences expert Dr Alexander Jarasch on a new wave of advanced data handling techniques that point the way to new drug discovery breakthroughs Notoriously, drug discovery is …

Continue ›››

How Industry Embraces Organ-on-Chips: A 2024 Status Report

Report highlights: We are currently at an exciting juncture where several big pharmaceutical companies have started adopting such models and conducted several exploratory studies The last 4 years have witnessed …

Continue ›››

A Booming Anti-Obesity Drug Discovery Landscape at a Glance (With Challenges)

This Company Anonymized 1.8 Trillion Records to Support Biomedical Research

85% of Healthcare Leaders Investing or Plan to Invest in Gen AI, According to the Largest Survey

The Rise of Cyclic Peptides: Bridging the Gap in Modern Medicine

Insilico Medicine Unveils nach0: A Comprehensive LLM for Chemical and Biomedical Applications

4 Biotech Startups Developing Breakthrough Drug Modalities

The Growing Impact of AI in Healthcare

From Diagnosis to Treatment: The Impact of AI on Rare Disease Drug Development

Optimising Drug Discovery R&D with Graphs

How Industry Embraces Organ-on-Chips: A 2024 Status Report

How AI Empowers Biomarker-Driven Clinical Trials

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies